Humanized NKP46 Animal Models for Accurate Immune Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional drug research and development methods, including in vitro screening and conventional animal models, fail to accurately replicate human disease states and immune interactions, leading to high failure rates and discrepancies between animal trial results and clinical outcomes.
Innovation Solution
Development of genetically modified animal models that express human or chimeric NKP46, allowing for the study of NKP46 gene function, screening of anti-human NKP46 antibodies or drugs, and evaluation of their efficacy in human-like immune responses and cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional animal models are used for drug screening, then the complexity of the model is low and ease of operation is maintained, but the reliability of results does not reflect human disease states accurately
Solution Approach 1:
The patent creates a copy of the human NKP46 gene and introduces it into the animal genome, replacing or supplementing the endogenous animal NKP46 gene. This copying approach allows the animal model to express human NKP46 protein, thereby accurately representing human disease states and immune responses while maintaining the overall simplicity of the animal model system.
2Reliability
If in vitro screening approaches are used, then the ease of operation and cost are favorable, but the reliability of drug development results is low due to inability to provide body environment
Solution Approach 1:
The patent introduces human NKP46 expression into animal models as an intermediary system that bridges in vitro screening and human clinical trials. The animal model with humanized NKP46 serves as a mediator that provides the body environment necessary for reliable drug evaluation while maintaining the productivity and efficiency advantages of animal-based testing.
3Measurement precision
If humanized animal models are developed, then the reliability and accuracy of human antibody screening is improved, but the difficulty of manufacture and time required increases
Solution Approach 1:
The patent employs preliminary action by first establishing the human NKP46 gene sequence and identifying appropriate animal model systems before conducting the actual gene introduction and model development. This preparatory work, including sequence analysis and model selection, streamlines the subsequent model creation process and reduces overall development time while ensuring measurement precision.
Data Source
AI summary
Genetically modified non-human animals that express a human or chimeric (e.g., humanized) NKP46, and methods of use thereof.